Methylene blue alone vs MB + NAD+ — mitochondrial research stacks
Methylene blue (MB) and NAD+ both target mitochondrial function but at different points in the electron transport chain. MB is a redox-active dye that accepts electrons in the cytosol and donates them to cytochrome c / complex IV in mitochondria — providing an alternative electron transport pathway that bypasses dysfunctional complexes I/III. NAD+ is the substrate for complex I and is also the cofactor for sirtuins and PARPs. The research-stack rationale is that the two compounds support different stages of the ETC and produce additive effects on mitochondrial respiration in cell-culture and animal-model literature. Direct head-to-head trials don't exist; the combination is a research-protocol concept rather than a clinically-tested therapy.
Side-by-side
| Methylene Blue 100 mL / 30% | MB + NAD+ research stack | |
|---|---|---|
| Compound class | Phenothiazinium dye (alternative electron carrier) | Combination — see individual entries |
| ETC position | Complex IV / cytochrome c bypass | Complex I (NAD+) + Complex IV (MB) |
| Other roles | NOS inhibition, monoamine oxidase inhibition | Sirtuin / PARP cofactor (NAD+) + above (MB) |
| Half-life | ~5 hours | Varies by component |
| Research focus | Cognition, neurodegeneration, mitochondrial dysfunction | Mitochondrial-aging research |
| Clinical trials | Phase 1/2 in Alzheimer's, sepsis-induced encephalopathy | None for combination |
What to know
- ·MB has FDA approval for methaemoglobinaemia and ifosfamide-induced encephalopathy at clinical doses (~50-200 mg). 'Microdose MB' research uses much lower doses (~0.5-4 mg) for cognitive/mitochondrial effects.
- ·NAD+ alone via IV is well-characterised; oral NMN/NR are the cheaper precursor approaches.
- ·The combination is research-context only — no formal clinical trial of MB + NAD+ exists.
- ·MB at high doses interacts with serotonergic medications (SSRIs, MAOIs) producing serotonin syndrome — significant safety consideration.
- ·Both are research-use only on this catalogue.
Where the literature diverges
MB literature is dominated by Atamna's neurodegeneration / cognitive research (UCSF) and Rojas's group at U Texas Austin (MB + light, photobiomodulation synergy). NAD+ literature is enormous and dominated by aging/sirtuin research from Sinclair (Harvard), Brenner (City of Hope), and others. The combination is a longevity-research concept that hasn't produced standalone clinical-trial data.
FAQ
Is the combination synergistic?+
In cell-culture and animal-model research, yes — different ETC positions produce additive respiration improvements. Whether this translates to clinical endpoints is research-context speculation, not established.
Why low-dose methylene blue specifically?+
Above ~10 mg/kg MB becomes pro-oxidant rather than antioxidant — the dose-response curve is biphasic. Microdose research targets the ~0.5-4 mg range where the alternative-electron-carrier benefit predominates without redox toxicity.
This is a research-context comparison of compound mechanism and published trial outcomes. Not medical advice. Both compounds are research-use only when sold by Omega Grade — for in vitro laboratory investigation, not human or veterinary administration.
- ResearchMethylene Blue 100 mL / 30%
Methylene blue is a phenothiazine dye with extensive applications in cellular and mitochondrial research, histology, and redox biology.
- ResearchSemax 11 mg
Semax is a synthetic heptapeptide analogue of ACTH(4-10). Registered in Russia for stroke and cognitive indications; Western research-use only.
- ResearchSemax Nasal 10 mg
Pre-filled nasal-spray format of Semax — the intranasal delivery route studied in the Russian clinical literature.